Reading the tape
NASDAQ: SGHT
Sight Sciences, Inc.
Healthcare · Medical - Devices
Market Cap
$227.91M
52w High
$9.24
52w Low
$2.74
P/E
-5.83
Volume
190.55K
Outstanding Shares
54.01M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 44.03%Revenue (TTM): -3.13%FCF (TTM): -31.59%P/S: 28th pct
What changed
The stock rose 44.03% over the last year. Revenue declined 3.13% over the trailing twelve months. Operating margin moved from -63.27% to -47.96%. Free cash flow declined 31.59% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -47.96%. A decisive move in revenue — currently down 3.13% — would be the clearest signal to resolve the ambiguity.
Company profile
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.
CEOPaul Badawi
SectorHealthcare
IndustryMedical - Devices
Employees216
IPO dateJul 15, 2021
Valuation
Forward P/E—
EV/EBITDA-9.90
Enterprise value$362.35M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth6.87%
Gross margin86.17%▲0.79%vs FY2024
Operating margin-47.96%▲24.21%vs FY2024
ROE-60.1%▼2.12%vs FY2024
Analyst consensus
RatingBuy
Target price$9.67▲129.15%
4
Buy
4
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$0.19 · Revenue est $18.55M
View